Immune cells after prolonged Natalizumab therapy: Implications for effectiveness and safety

Acta Neurologica Scandinavica

Volumn 128, Issue 1, 2013, Pages

  Marousi, S ^a   Karkanis, I ^a   Kalamatas, T ^a   Travasarou, M ^a   Paterakis, G ^a   Karageorgiou, C E ^a  

^a KAT HOSPITAL   (Greece)

Author keywords

Clinical response; Immune cell phenotypes; Multiple sclerosis; Natalizumab; Progressive multifocal leucoencephalopathy

Indexed keywords

GLATIRAMER; INTERFERON; NATALIZUMAB;

ADULT; ARTICLE; B LYMPHOCYTE; BASOPHIL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; EOSINOPHIL COUNT; EXPANDED DISABILITY STATUS SCALE; FEMALE; GENDER; GROUPS BY AGE; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MONOCYTE; MULTIPLE SCLEROSIS; NATURAL KILLER T CELL; NEUTROPHIL COUNT; PERIPHERAL LYMPHOCYTE; PHENOTYPE; TREATMENT DURATION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 84879182787     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12080     Document Type: Article

References (15)

1. Polman CH, O'connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
2. Ghosh S, Goldin E, Gordon FH et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32.
3. Stuve O, Marra CM, Jerome KR et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59:743-7.
4. Krumbholz M, Meinl I, Kumpfel T, Hohlfeld R, Meinl E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008;71:1350-4.
5. Putzki N, Baranwal MK, Tettenborn B, Limmroth V, Kreuzfelder E. Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells. Eur Neurol 2010;63:311-7.
6. Papayannopoulou T. Mechanisms of stem-/progenitor-cell mobilization: the anti-VLA-4 paradigm. Semin Hematol 2000;37:11-8.
7. Hellwig K, Gold R. Progressive multifocal leukoencephalopathy and natalizumab. J Neurol 2011;258:1920-8.
8. Fox RJ, Rudick RA. Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology 2012; 78: 436-7.
9. Bloomgren G, Richman S, Hotermans C et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870-80.
10. Stuve O, Marra CM, Bar-Or A et al. Altered CD4 + /CD8 + T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 2006;63:1383-7.
11. Berger JR, Kaszovitz B, Post MJ, Dickinson G. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med 1987;107:78-87.
12. Houff SA, Major EO, Katz DA et al. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 1988;318:301-5.
13. Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis 2002;186(Suppl 2):S180-6.
14. Calabresi PA, Giovannoni G, Confavreux C et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007;69:1391-403.
15. Brown BA. Natalizumab in the treatment of multiple sclerosis. Ther Clin Risk Manag 2009;5:585-94.